HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year

Deep News05-29

HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive development trend. For the full year 2025, the company achieved operating revenue of 31.629 billion yuan, representing a year-on-year increase of 13.02%. Net profit attributable to shareholders of the listed company reached 7.711 billion yuan, a year-on-year increase of 21.69%. In the first quarter of 2026, operating revenue was 8.141 billion yuan, up 12.98% year-on-year, with net profit attributable to shareholders of the listed company at 2.282 billion yuan, an increase of 21.78% year-on-year. The company consistently places high importance on the interests of all shareholders, is committed to developing its core business, promoting sustainable performance growth, and rewarding shareholders through continued progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130414847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130414847","market":"us","top_or_hot":-1,"title":"HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year","media":"Deep News","content":"<p>HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive development trend. For the full year 2025, the company achieved operating revenue of 31.629 billion yuan, representing a year-on-year increase of 13.02%. Net profit attributable to shareholders of the listed company reached 7.711 billion yuan, a year-on-year increase of 21.69%. In the first quarter of 2026, operating revenue was 8.141 billion yuan, up 12.98% year-on-year, with net profit attributable to shareholders of the listed company at 2.282 billion yuan, an increase of 21.78% year-on-year. The company consistently places high importance on the interests of all shareholders, is committed to developing its core business, promoting sustainable performance growth, and rewarding shareholders through continued progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-29 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive development trend. For the full year 2025, the company achieved operating revenue of 31.629 billion yuan, representing a year-on-year increase of 13.02%. Net profit attributable to shareholders of the listed company reached 7.711 billion yuan, a year-on-year increase of 21.69%. In the first quarter of 2026, operating revenue was 8.141 billion yuan, up 12.98% year-on-year, with net profit attributable to shareholders of the listed company at 2.282 billion yuan, an increase of 21.78% year-on-year. The company consistently places high importance on the interests of all shareholders, is committed to developing its core business, promoting sustainable performance growth, and rewarding shareholders through continued progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997244956.HKD","symbol_name":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","start_time":0,"source_url":"","article_id":"1130414847","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130414847","pubTimestamp":1780060849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","01276":"恒瑞医药","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0188":"融资融券","BK0028":"国家队","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0183":"MSCI概念","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0012":"证金概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1191":"制药","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0196":"行业龙头","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0060":"抗癌","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC"},"translate_title":"恒瑞医药公布2025年营收316.3亿元同比增长13.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA stated that while secondary market fluctuations are influenced by multiple factors, the company's operational performance continues to improve steadily, with an overall positive development trend. For the full year 2025, the company achieved operating revenue of 31.629 billion yuan, representing a year-on-year increase of 13.02%. Net profit attributable to shareholders of the listed company reached 7.711 billion yuan, a year-on-year increase of 21.69%. In the first quarter of 2026, operating revenue was 8.141 billion yuan, up 12.98% year-on-year, with net profit attributable to shareholders of the listed company at 2.282 billion yuan, an increase of 21.78% year-on-year. The company consistently places high importance on the interests of all shareholders, is committed to developing its core business, promoting sustainable performance growth, and rewarding shareholders through continued progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130414847","isCrawlerRequest":true}